Search

Background: Influenza poses a potential public health threat among healthcare professionals since an infected healthcare professional can spread the virus to patients at higher risk as well as his/her own family members and colleagues. Annual influenza vaccination is the most effective way to protect HCPs., Aim: This study was conducted to determine whether demand for and beliefs about influenza vaccination have changed among healthcare professionals in the COVID-19 era and the factors that might have influenced them in the early phase of the pandemic when COVID-19 vaccines were eagerly awaited., Patients and Methods: This observational descriptive study was conducted between November 16, and December 15, 2020. A total of 317 healthcare professionals completed an online survey. Bivariate analysis and binary logistic regression analysis were performed., Results: Nineteen (6.0%) healthcare professionals were regularly vaccinated against influenza every year, and 199 (62.8%) had never been vaccinated. During the 2019-2020 season, 30 (9.5%) participants had been vaccinated and the proportion desiring to be vaccinated against influenza during the 2020-2021 season was 49.8% (n = 158). The results revealed that those with chronic diseases, those who believed they had adequate information about influenza vaccination and those who believed healthcare professionals should be vaccinated against influenza regularly every year, respectively, had 3.5 times, 4.7 times, and 11 times higher vaccination rates., Conclusion: Although the proportion of healthcare professionals with the intention to be vaccinated for influenza increased with the COVID-19 pandemic, it is still not high enough. Influenza vaccination rates should be promoted by in-service training programs., Competing Interests: None

Background: The relationship between Coronavirus Disease 2019 (COVID-19) and acute kidney injury (AKI) is well-established. However, a comprehensive evaluation of kidney outcomes in the long-term course of COVID-19 is not yet been performed. The aim of this study is to investigate whether chronic kidney disease (CKD) develops within six months after hospital discharge in COVID-19 patients who did not have kidney damage at the time of admission to the hospital., Patients and Methods: This single-center retrospective study investigated a total of 1008 participants selected from 7500 COVID-19 patients with real-time reverse transcription-polymerase chain reaction (RT-PCR) positivity. All patients had mild/moderate or severe COVID-19. Patients were randomly selected from inpatient and outpatient settings. Critical COVID-19 patients were not included., Results: The mean age of the patients was 56.57 ± 16.30 years, and 69.9% of them were male. The comorbidity percentages of the participants were as follows; 19.5% coronary artery disease (CAD), 28.6% diabetes mellitus (DM), 36.2% hypertension (HT), 3.1% cerebrovascular obstruction (CVO), 1.7% malignancy, 2.6% chronic obstructive pulmonary disease (COPD), 9.4% asthma, % 1.7 dementia, 9.9% hyperlipidaemia, and 1.7% hepatitis B virus (HBV). Kidney function tests of these patients at first admission and 6 months later were compared to reveal the relationship between COVID-19 and CKD. Serum glucose, sodium estimated glomerular filtration rate (eGFR), and uric acid levels were found to be high in the post-COVID-19 period (P = 0.001). However, there were a decrease in serum albumin, potassium, alanine aminotransferase (ALT), C-reactive protein (CRP), aspartate aminotransferase (AST), lactate dehydrogenase (LDH), and gamma-glutamyl transferase (GGT) levels (P = 0.001). The difference between the first measurement of serum urea and creatinine (Cr) levels and the measurement 6 months later was not statistically significant (P = 0.102 and P = 0.300, respectively)., Conclusions: Those who survived the mild/moderate and severe clinical manifestations of COVID-19 did not exhibit any risk of kidney outcomes after the acute phase of the disease, suggesting that the kidney can protect itself over a long period of time., Competing Interests: None

Background: It has been reported that the most affected organ by the coronavirus disease 2019 (COVID-19) is the lung, closely followed by the kidney., Aim: Over the course of the COVID-19, the factors affecting mortality in acute kidney injury requiring renal replacement therapy (AKI-RRRT) have not been known. This study was conducted in order to shed light on this issue., Patients and Methods: There were 64 patients in total. Subjects were divided into two groups. Group 1 consisted of a control group that comprised 33 subjects who did not have AKI during the time in which they were infected with COVID-19. Group 2 was COVID-19 related AKI requiring renal replacement therapy (COVID-19 AKI-RRRT), which included 31 subjects who were exposed to AKI-RRRT., Results: İn Group 2, 27 (87%) patients died and 4 (13%) patients were recovered. The predominance of comorbidity and presence of more than one additional disease (p < 0.05), the excessive number of inpatients in intensive care unit (ICU) (p < 0.05), high mortality rates (p < 0.05), advanced age (p < 0.05), and long hospitalization periods (p < 0.05) were evident in Group 2. Serum levels of variables such as white blood cells (WBC), neutrophils, C-reactive protein (CRP), procalcitonin (PCT), ferritin, D-dimer, glucose, lactate dehydrogenase (LDH), and prothrombin time (PT) were high for patients in the Group 2 (p < 0.05) group. However, serum levels of lymphocyte, hemoglobin (HGB), and albumin were low., Conclusions: It can be argued that COVİD-19 AKI-RRRT is associated with higher mortality., Competing Interests: None